Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
Behandeling van anale HSIL verlaagt risico anuscarcinoom
aug 2022 | HIV, Maag-darm-leveroncologie, Virale infecties